Vaccine News and Research

Latest Vaccine News and Research

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

PharmAthene, Inc. announced today that it has achieved an important program milestone in its recombinant protective antigen (rPA) anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United Kingdom. The stability data were prepared utilizing a variety of analytical methods and a well characterized mouse challenge potency assay.

14 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

Patient-centered medical home boosts diabetes outcomes, health

A health-care delivery model called patient-centered medical home (PCMH) increased the percentage of diabetes patients who achieved goals that reduced their sickness and death rates, according to health researchers.

14 Jul 2011

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011

Swine flu vaccine and risk of Guillain-Barré Syndrome

In a large five nation study from Europe it was seen that the use of adjuvanted vaccines against the pandemic H1N1 influenza virus probably did not increase the risk of Guillain-Barré Syndrome (GBS), but the investigators could not firmly rule out a slightly greater chance of suffering the paralytic condition.

13 Jul 2011

Daily pill ‘combo’ prevents HIV transmission: New African study

According two studies in Africa, taking a daily pill containing either one or two anti-HIV drugs can reduce transmission of the virus by as much as three-quarters among heterosexual couples. This is an encouraging finding that could help focus on AIDS prevention. The results were so compelling that the larger study was halted early and the drugs given to all the participants, researchers said Wednesday.

13 Jul 2011

NIH grants $70M over five years to help search for HIV cure

NIH announced on Monday it will provide $70 million over five years to three collaborations searching for an HIV/AIDS cure, making it "the largest single investment yet … into finding a way to rid the virus from the body or at least reduce levels to the point that infected people can stop taking anti-HIV drugs - which many researchers until recently viewed as a hopeless quest," ScienceInsider reports.

13 Jul 2011

Rapid method can predict immune responses against flu vaccines

Researchers at the Emory Vaccine Center have developed a method for predicting whether someone will produce high levels of antibodies against a flu shot a few days after vaccination.

12 Jul 2011

UNC receives $32 million federal grant to eradicate HIV infection

Researchers at the University of North Carolina at Chapel Hill have been awarded a $32 million, five-year federal grant to develop ways to cure people with HIV by purging the virus hiding in the immune systems of patients taking antiretroviral therapy.

12 Jul 2011

Haiti passed up cholera vaccine offer, Crucell CEO says

Ronald Brus, CEO of the Dutch vaccine maker Crucell, said Haiti did not accept an offer of tens of thousands of cholera vaccine doses late last year, the Financial Times reports.

12 Jul 2011

New research strategy for eradicating HIV from the body

An international team led by researchers from the University of California, San Francisco and the nonprofit Vaccine and Gene Therapy Institute of Port St. Lucie, Fla., has received a major grant from the National Institutes of Health to develop a strategy to eradicate HIV from the body.

12 Jul 2011

Ipsen, Salk Institute renew Life Sciences Program

Ipsen and The Salk Institute for Biological Studies announced today that they are renewing the Ipsen Life Sciences Program at The Salk Institute.

12 Jul 2011

Merck researchers to participate in two new collaborative efforts to study HIV latency

Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.

12 Jul 2011

Hutchinson Center receives $20M NIH grant to eradicate HIV infection

Whether a stem cell transplant using an HIV-infected person's own genetically modified immune cells can become a cure for the disease is the focus of a new $20 million, five-year research grant award announced today by the National Institutes of Health to Fred Hutchinson Cancer Research Center.

12 Jul 2011

New ‘world-first’ Malaria vaccine in the pipeline

Australian researchers have potentially created a ‘world-first’ malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.

12 Jul 2011

Viewpoints: N.Y. health exchange stalemate; Dick Cheney's heart; vaccine debate refuses to die

Just in case you hadn't noticed, no one has elected Grover Norquist to anything. Still, he looms as a major obstacle to Congress reaching a deficit-reduction agreement needed to raise the federal debt ceiling. … what's revealing about Norquist's passionate advocacy against taxes is that it virtually ignores the main causes of bigger government: Social Security and Medicare.

12 Jul 2011

NIAID awards $14 million a year for new HIV research

Three research teams focused on developing strategies that could help to rid the body of HIV are receiving grants totaling more than $14 million a year, for up to five years, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announced today.

11 Jul 2011

New gonorrhea strain resistant to all antibiotics isolated in Japanese woman

A new strain of the sexually transmitted disease gonorrhea that is resistant to all known antibiotic treatments has been isolated from a female sex worker in Japan, according to Magnus Unemo of the Swedish Reference Laboratory for Pathogenic Neisseria, Reuters reports. Unemo is set to present his findings at a conference of the International Society for Sexually Transmitted Disease Research in Quebec on Monday.

11 Jul 2011

Microneedle patches may target dentritic cells more efficiently and induce immunity against HIV

Applying a vaccine patch to the skin with thousands of tiny micro-needles could help boost the body's immune response and prevent the spread of life-threatening infections like HIV and TB, a major Cardiff University study aims to uncover.

11 Jul 2011

iBio successfully produces human plasma proteins using proprietary technology

iBio, Inc. today announced successful production of human plasma proteins using its proprietary iBioLaunch technology. Human alpha 1-antitrypsin and human C1 esterase inhibitor were successfully produced at high yield in green plants via the Company's proprietary iBioLaunch technology. Both of these proteins are important therapeutic products, but until now they have been made from human blood.

11 Jul 2011